Clinical Trial Update: United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

View source ↗

Summary

A completed UK patient-preference study evaluated Somatuline Autogel (lanreotide) and treatment administration settings for neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Somatuline Autogel (lanreotide)

Snippet

Sponsor: Ipsen | Conditions: Neuroendocrine Tumours (NET) | Status: COMPLETED